Cameroon vs Lebanon: Average cost of drugs for extensively drug-resistant tuberculosis
Cameroon
227 constant 2022 US$
in 2024
Lebanon
5 constant 2022 US$
in 2024
Cameroon rank
54th
Lebanon rank
56th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Cameroon
- Lebanon
How they compare
Cameroon currently reports 227 constant 2022 US$ against 5 constant 2022 US$ in Lebanon, a difference of 222 constant 2022 US$.
That makes Cameroon's figure about 45.4 times Lebanon's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Lebanon ahead.
Cameroon ranks 54th and Lebanon ranks 56th of 56 countries.
Cameroon has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cameroon | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,251 constant 2022 US$ | 3,953 constant 2022 US$ | 298 constant 2022 US$ | Cameroon |
| 2020s | 2,687 constant 2022 US$ | 633.2 constant 2022 US$ | 2,054 constant 2022 US$ | Cameroon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Cameroon or Lebanon?
- Cameroon, at 227 constant 2022 US$ against 5 constant 2022 US$ in Lebanon as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Cameroon and Lebanon?
- 222 constant 2022 US$, with Cameroon ahead.
- How many years of comparable data are there for Cameroon and Lebanon?
- 8 years are reported by both, from 2017 to 2024.
- How do Cameroon and Lebanon rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Cameroon ranks 54th and Lebanon ranks 56th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.